Triple
T13959263
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Gamaleya Research Institute |
E335748
|
entity |
| Predicate | developed |
P73
|
FINISHED |
| Object | Sputnik Light COVID-19 vaccine |
E1071419
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Sputnik Light COVID-19 vaccine | Statement: [Gamaleya Research Institute, developed, Sputnik Light COVID-19 vaccine]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sputnik Light COVID-19 vaccine Context triple: [Gamaleya Research Institute, developed, Sputnik Light COVID-19 vaccine]
-
A.
Sputnik V COVID-19 vaccine
chosen
Sputnik V COVID-19 vaccine is a Russian-developed viral vector vaccine against COVID-19 that gained global attention as one of the first vaccines authorized for use during the pandemic.
-
B.
Vaxzevria COVID-19 vaccine
Vaxzevria COVID-19 vaccine is a viral vector coronavirus vaccine created to prevent COVID-19 infection and severe disease in adults.
-
C.
Sinovac
Sinovac is a Chinese biopharmaceutical company best known globally for developing the inactivated COVID-19 vaccine CoronaVac.
-
D.
Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine is a single-dose, viral vector-based coronavirus vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, for the prevention of COVID-19.
-
E.
BNT162b2
BNT162b2 is an mRNA-based COVID-19 vaccine, co-developed by BioNTech and Pfizer, that became one of the first widely authorized vaccines against SARS-CoV-2.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d81c61f3508190aaf2ca0dc0002c59 |
completed | April 9, 2026, 9:38 p.m. |
| NER | Named-entity recognition | batch_69de2e7b2f908190aa32f22298964746 |
completed | April 14, 2026, 12:09 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69fbac8e47d48190a1d5e841810fe50c |
completed | May 6, 2026, 9:03 p.m. |
Created at: April 9, 2026, 10:17 p.m.